The Leukemia and Lymphoma Society is at the forefront of the fight to cure blood cancer. It is the largest nonprofit dedicated to creating a world without blood cancer. They invested 1.6 billion dollars since 1949 in groundbreaking research, pioneering many of today’s most innovative approaches. The mission of the leukemia and lymphoma society is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, and improve the quality of life of patients and their families. It offers free education and support for blood cancer patients and families. They provide personalized, one-on-one support, including assistance with identifying and enrolling in a clinical trial. They drive policy changes that accelerate the breakdown of new cancer treatments and break down barriers to care. They make thoughtful investments in blood cancer research that will lead to scientific breakthroughs that will improve and save the lives of patients. The LLS research team oversees the organizations research agenda and manages portfolios to support cutting-edge research for every type of blood cancer. LLS awards grants for studies that range from basic blood cancer research to clinical trials. LLS has a mission-driven, strategic venture called TAP, therapy acceleration program. This is a philanthropic initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care. There are currently over 20 active clinical studies with TAP-supported therapies.
Leukemia & Lymphoma Society | Blood Cancer Leaders | LLS. (n.d.). https://www.lls.org/
The Lymphoma & Leukemia Society is a 501 charitable organization dedicated to making a positive impact on the lives of patients experiencing blood-related cancers as well as their families through large donations towards blood-cancer research, providing free resources, educating the masses, and supporting both patients and the family members affected by their diagnosis. In addition to the remarkable services provided by the Lymphoma & Leukemia Society, the organization’s mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. This organization was founded after the tragic passing of the then-sixteen-year-old boy, Robert “Robbie” Roesler de Villiers. After his untimely death, his family banded together out of frustration for the lack of treatment options available for other patients just like him. Their dedication to relentlessly searching for a cure fostered a community that has now boomed into the Lymphoma and Leukemia Society that we know today.
In the present, LLS is focused on enhancing medical discoveries & research dedicated to better understanding how genetics plays a role in the eventual development of blood cancers. By donating to such a unique cause, the LLS is able to help further medical innovation and pioneer the genetic frontier. Genetics are not well understood in their role when it comes to assessing the way cancer develops. With such a breakthrough, patients may potentially be able to enter a pre-screen that can help ascertain whether someone is at a higher risk of developing a blood cancer or not. In doing so, prophylactic treatment or preparations may be made to help treat a patient prior to the devastating effects that Lymphoma or Leukemia may have on a patient if it were not caught early on.
In addition to helping further medical advancements in terms of research, LLS also specializes in patient advocacy and policy. A few of the main topics that the LLS are moving to make revolutionary changes to include improving access to sensitive medications that are necessary for cancer patients to ensure survival, enhancing the sustainability of the healthcare system, promoting access to insurance for cancer patients due to high medication costs and treatment, improving the cancer care that is provided to vulnerable populations such as pediatric patients, and accelerating the road to new cutes.
The LLS has an office dedicated solely to policy and changes. The policy office of the LLS is focused on enhancing policy agenda aimed at accelerating the development of new treatments for cancer and breaking down the barriers to care that patients often encounter. The Office of Public Policy (also known as the OPP) filters issues into two separate categories to ensure a proper agenda. These two fields include: How does the issue impact blood cancer patients and survivors? As well as What is the political and practical viability of the policies that have been proposed as a solution to the issue at hand? Through these questions, the OPP is able to discern what steps need to be taken in order to break down barriers that stand in their way.
A review of the Leukemia & Lymphoma Society
The Leukemia and Lymphoma Society (LLS) is a non-profit organization dedicated to funding research for blood cancers and ensuring access to treatments for all patients. In their mission statement, they state that their purpose is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, as well as to improve the quality of life of patients and their families.
Blood cancers are a deadly disease, and it requires the support of the community to help fight it. One person is diagnosed with a blood cancer every 3 minutes in the U.S., and more than 1/3 of the patients do not survive 5 years after their diagnosis. Furthermore, every 9 minutes, someone in the U.S. dies of a blood cancer.
Leukemia is a cancer of the blood and bone marrow. There are many types of leukemia, and the rate at which the disease progresses and cancerous cells replace normal ones differs with each type. Common types include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), etc.
Lymphoma is a cancer that develops in the lymphatic system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Hodgkin lymphoma can be distinguished by the development of Reed-Sternberg cells, which are large, cancerous cells found in the affected tissues. Hodgkin lymphoma is one of the most curable forms of cancer. NHL can be distinguished from Hodgkin by certain characteristics of the cancer cells. Most patients have the B-cell type, while others have the T-cell or NK-cell type.
To help LLS continue to fund research and improve outcomes for cancer patients, one can donate or volunteer in activities from fundraising to patient support or education.
· Leukemia. Leukemia and Lymphoma Society. https://www.lls.org/leukemia. Accessed June 8, 2020.
· Lymphoma. Leukemia and Lymphoma Society. https://www.lls.org/lymphoma. Accessed June 8, 2020.